CVML advised AB Science on a EUR 34.0 million private placement of new ordinary shares.
The shares were subscribed by qualified investors specialized in the pharmaceutical or biotechnological sector.
The placement was done in two tranches, with a first settlement delivery of the newly issued shares on March 29, 2017, and a second settlement delivery on April 4, 2017.
The private placement was managed by Chardan Capital Markets as Bookrunner and Lead Placement Agent.
The CVML team included Paris-based partner Pierre Treille and associate Mickaël Guillemot.
Founded in 2001 and listed on Euronext since 2010, AB Science is a pharmaceutical company specialized in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells.